文献速递银屑病与炎症性皮肤病

Tapinarof乳膏治疗斑块状银屑病的一年安全性和有效性:PSOARING 3试验结果

One-year safety and efficacy of tapinarof cream for the treatment of plaque psoriasis: Results from the PSOARING 3 trial.
PubMed 文献 · J Am Acad Dermatol · 2022-06-27

PSOARING 3是一项开放标签扩展研究,纳入完成两项12周3期试验的成人轻至重度斑块状银屑病患者,接受tapinarof 1%乳膏每日一次治疗最长40周并随访4周。结果显示40.9%患者达到完全清除(PGA=0),达到PGA=0者停药后缓解效应平均持续130.1天,未观察到新的安全性信号。

要点

  • 40.9%患者达到完全疾病清除(PGA=0),58.2%基线PGA≥2者达到PGA=0或1。
  • 达到PGA=0者停药后缓解效应平均持续130.1天。
  • 最常见不良事件为毛囊炎(22.7%)、接触性皮炎(5.5%)和上呼吸道感染(4.7%)。

核心结论

  • 疗效在12周试验后继续改善,完全疾病清除率达40.9%,停药后缓解效应约4个月,治疗期间疗效持久,安全性一致。

研究设计与样本

  • 开放标签扩展研究,纳入完成两项12周3期试验的成人轻至重度斑块状银屑病患者,接受tapinarof 1%乳膏每日一次治疗最长40周并随访4周。
  • 共91.6%(n=763)符合条件的患者入组。

主要发现

  • 40.9%患者达到完全疾病清除(PGA=0)。
  • 58.2%基线PGA≥2的患者达到PGA=0或1。
  • 达到PGA=0的患者停药后缓解效应平均持续130.1天。
  • 未观察到新的安全性信号。
  • 最常见不良事件为毛囊炎(22.7%)、接触性皮炎(5.5%)和上呼吸道感染(4.7%)。

局限性

  • 开放标签研究。
  • 无对照。
  • 可能不能推广至所有类型的银屑病。
  • 缓解效应/应答率可能被低估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Tapinarof cream 1% once daily, an aryl hydrocarbon receptor-modulating agent, was significantly more efficacious than vehicle and well tolerated in two 12-week phase 3 trials in adults with mild to severe plaque psoriasis. OBJECTIVE: To assess long-term safety, efficacy, remittive effect, durability of response, and tolerability of tapinarof. METHODS: Patients completing the 12-week trials were eligible for 40-weeks' open-label treatment and 4-weeks' follow-up. Treatment was based on the Physician Global Assessment (PGA) score. Patients entering with PGA≥1 received tapinarof until PGA = 0. Patients with PGA = 0 discontinued tapinarof and were monitored for remittive effect. Patients with PGA≥2 were re-treated until PGA = 0. RESULTS: Overall, 91.6% (n = 763) of eligible patients enrolled; 40.9% of patients achieved complete disease clearance (PGA = 0), and 58.2% entering with PGA≥2 achieved PGA = 0 or 1. Mean duration of off therapy remittive effect for patients achieving PGA = 0 was 130.1 days. No new safety signals were observed. Most frequent adverse events were folliculitis (22.7%), contact dermatitis (5.5%), and upper respiratory tract infection (4.7%). LIMITATIONS: Open-label; no control; may not be generalizable to all forms of psoriasis; remittive effect/response rate potentially underestimated. CONCLUSIONS: Efficacy improved beyond the 12-week trials, with a 40.9% complete disease clearance rate, ∼4-month off therapy remittive effect, durability on therapy, and consistent safety.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Strober B, Stein Gold L, Bissonnette R, et al. One-year safety and efficacy of tapinarof cream for the treatment of plaque psoriasis: Results from the PSOARING 3 trial. J Am Acad Dermatol. 2022. PMID: 35772599. doi:10.1016/j.jaad.2022.06.1171

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。